<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401882</url>
  </required_header>
  <id_info>
    <org_study_id>2006-008</org_study_id>
    <nct_id>NCT00401882</nct_id>
  </id_info>
  <brief_title>Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial</brief_title>
  <acronym>Shock n Block</acronym>
  <official_title>Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Haines, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the effectiveness of metoprolol, a &quot;beta&#xD;
      blocker,&quot; in treating patients in the hospital with a cardiac arrest. It will be given&#xD;
      intravenously (given into a vein). The subjects who will take part in this study are 18 years&#xD;
      of age or older, are experiencing a cardiac arrest in the hospital, and are in a life&#xD;
      threatening situation. Patients who develop a cardiac arrest require prompt electrical&#xD;
      defibrillation (electrical shocks) to restore the normal beating rhythm of the heart. In&#xD;
      patients who do not respond to electrical defibrillation, current standard of care recommends&#xD;
      the use of medications which have been shown to be of unknown benefit. Some people recover&#xD;
      from a cardiac arrest, but many people do not. We want to learn whether giving metoprolol&#xD;
      will improve survival of patients with a cardiac arrest. A total of 100 patients will be&#xD;
      enrolled in the study. Patients will receive either the standard of care with the drug&#xD;
      epinephrine or the standard of care plus metoprolol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) is a catastrophic event and most commonly results from acute&#xD;
      ventricular tachyarrhythmias (abnormal and lethal heart rhythms). It is often triggered by&#xD;
      acute coronary events, which may occur in persons without known cardiac disease or in&#xD;
      association with structural heart disease. Advanced therapies such as thrombolytic agents,&#xD;
      percutaneous coronary intervention, and implantable cardioverter defibrillators are of no&#xD;
      value to thousands of victims who do not survive. Many instances of SCD cannot be predicted&#xD;
      and any intervention directed toward the general population would have to be applied to an&#xD;
      estimated 1000 persons for every 1 person in whom SCD might be prevented. Thus, it would be&#xD;
      reasonable to develop new treatment strategies to improve response to resuscitative efforts.&#xD;
&#xD;
      Prompt electrical defibrillation (electrical shocks) is the treatment of choice in persons&#xD;
      who develop SCD due to ventricular fibrillation (VF) or pulseless ventricular tachycardia&#xD;
      (pVT). However, in up to 25% of all cardiac arrests, patients develop shock resistant VF,&#xD;
      defined as VF persisting beyond three defibrillation attempts, and 87-97% of these patients&#xD;
      die. Medical therapy, including antiarrhythmic agents, sympathomimetic agents (i.e.&#xD;
      stimulants), and buffers have been relegated to a secondary role since there is little&#xD;
      evidence that they are of benefit and there use is considered indeterminate or class IIB.&#xD;
      Furthermore, the &quot;Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency&#xD;
      Cardiovascular Care&quot; of the American Heart Association and the International Liaison&#xD;
      Committee on Resuscitation recommend antiarrhythmic drugs as &quot;acceptable&quot; and &quot;probably&#xD;
      helpful&quot; in the treatment of VF that persists after three or more external defibrillation&#xD;
      shocks. It has been previously reported that the survival rate of hospital patients suffering&#xD;
      a cardiac arrest in which epinephrine was required was only 6%. Furthermore, Dorian et al&#xD;
      reported a survival to hospital admission of 22.8% in patients suffering an out of hospital&#xD;
      cardiac arrest and receiving amiodarone. It is believed that the acute effects of amiodarone&#xD;
      are due to the class II or beta blocking effects of the drug.&#xD;
&#xD;
      Resuscitation can only be considered successful if the survivor has no disabling cognitive&#xD;
      function. The American Heart Association/International Liaison Committee on Resuscitation&#xD;
      guidelines state that with a duration of cardiac arrest of &gt; 8 to 10 minutes, the frequency&#xD;
      of significant, permanent neurologic damage becomes unacceptably high. Newer treatment&#xD;
      modalities are needed to improve patient outcomes.&#xD;
&#xD;
      Epinephrine has been used during cardiopulmonary resuscitation for more than 100 years yet&#xD;
      its use has become controversial because it is associated with increased myocardial oxygen&#xD;
      consumption, ventricular tachyarrhythmias, and myocardial dysfunction during the period after&#xD;
      resuscitation. The current International Guidelines on Emergency Cardiac Care cite both&#xD;
      epinephrine and vasopressin as acceptable vasopressor drugs for treatment of refractory VF&#xD;
      but neither drug is acknowledged to be of proven benefit.&#xD;
&#xD;
      Beta blockers might improve patient outcomes by blunting the adverse affects of a&#xD;
      hyperadrenergic state that occurs during a cardiac arrest and by improving the balance&#xD;
      between myocardial oxygen supply and demand. Ditchey et al showed in an animal model that&#xD;
      pretreatment with a beta blocker prior to cardiac arrest followed by standard epinephrine&#xD;
      therapy results in reduced myocardial injury during CPR without compromising successful&#xD;
      defibrillation or post resuscitation left ventricular function.&#xD;
&#xD;
      The current research protocol was formulated in an attempt to develop new treatment options&#xD;
      for patients who develop an in-hospital VF or pVT arrest refractory to electrical&#xD;
      defibrillation with the specific goal of improving patient outcomes. The trial will utilize&#xD;
      pre-filled, blinded syringes of Metoprolol in patients who develop an in-hospital cardiac&#xD;
      arrest due to ventricular fibrillation or pulseless ventricular tachycardia (see study&#xD;
      protocol).&#xD;
&#xD;
      Sudden cardiac death (SCD) claims approximately 250,000 persons annually in the United&#xD;
      States. Ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) appear to be&#xD;
      responsible for 25-35% of all out of hospital episodes of sudden cardiac death. The reported&#xD;
      average survival to hospital discharge following in-hospital arrest is just as poor at&#xD;
      approximately 14-17% despite the development of widespread implementation of basic and&#xD;
      advanced cardiac life support. Current American Heart Association (AHA) guidelines recommend&#xD;
      prompt electrical defibrillation to reestablish organized electrical activity. Increasing&#xD;
      duration of VF (i.e. &quot;shock resistant VF&quot;) can result in two major adverse effects. First, an&#xD;
      increased duration can reduce the ability to terminate the arrhythmia8. Second, if VF&#xD;
      continues for more than four minutes, there is irreversible damage to the central nervous&#xD;
      system and other organs. Despite aggressive efforts, successful resuscitation from&#xD;
      out-of-hospital cardiac arrest occurs in only one third of patients and only about 10% of all&#xD;
      patients are ultimately discharged from the hospital, many of whom are neurologically&#xD;
      impaired. Also, the outcome of patients who suffer an in-hospital cardiac arrest is poor with&#xD;
      reported survival to hospital discharge rates of 10-15%. Thus, despite improvements and&#xD;
      advances in the treatment of heart disease, the outcome of patients experiencing SCD remains&#xD;
      poor.&#xD;
&#xD;
      Prompt and early defibrillation of VF or pVT has become the standard of care. Drug therapy&#xD;
      for shock resistant VF or pVT has been relegated to a secondary role since there is little&#xD;
      evidence that these agents are of benefit. As a result, their use is considered indeterminate&#xD;
      or class IIB. In addition, cardiac arrest and cardiopulmonary resuscitation are extreme forms&#xD;
      of stress that lead to the highest catecholamine levels ever recorded in both human or&#xD;
      experimental animal models. Endogenous catecholamine concentrations are high during&#xD;
      ventricular fibrillation even in the absence of epinephrine administration. Currently,&#xD;
      epinephrine is the vasopressor of choice for the treatment of cardiac arrest although&#xD;
      vasopressin has been used as an alternative. Of note, vasopressin has been shown to be&#xD;
      superior to epinephrine in patients with asystole however, its effects were similar to those&#xD;
      of epinephrine in the management of VF or pulseless electrical activity. Furthermore,&#xD;
      previous studies have raised concern that epinephrine's beta adrenergic effect may increase&#xD;
      the myocardial oxygen consumption of the fibrillating heart and predispose to&#xD;
      post-defibrillation dysfunction and cardiac arrhythmias.&#xD;
&#xD;
      Numerous animal studies have shown that beta adrenergic blockade reduces myocardial injury&#xD;
      and improves survival. Kudenchuk, et al undertook a study in patients with out of hospital&#xD;
      cardiac arrest due to ventricular fibrillation. Patients were randomized to receive either&#xD;
      amiodarone or placebo after three consecutive defibrillations and one dose of epinephrine.&#xD;
      The authors concluded that patients who received amiodarone had a higher rate of survival to&#xD;
      hospital admission. It is felt that the beneficial effects are related to the initial class&#xD;
      II or beta blocking properties of amiodarone. Furthermore, Dorian, et al reported a higher&#xD;
      rate of survival to hospital admission in patients who received amiodarone as compared to&#xD;
      lidocaine for shock resistant out-of-hospital ventricular fibrillation. Analysis from the&#xD;
      European Myocardial Infarct Amiodarone Trial and the Canadian Amiodarone Myocardial&#xD;
      Infarction Trial revealed an interaction between beta-blockers and amiodarone, specifically,&#xD;
      the combination group had a better survival and the interaction was statistically significant&#xD;
      for arrhythmic death or resuscitated arrest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult accrual&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Return of Spontaneous Circulation</measure>
    <time_frame>After electrical defibrillation</time_frame>
    <description>The patient will be evaluated for sufficiently stable and organized rhythm and blood pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival to Hospital Discharge</measure>
    <time_frame>from time of arrest to discharge or death</time_frame>
    <description>the number of patients who are alive at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Precordial Shocks Required After the Administration of Metoprolol or Epinephrine</measure>
    <time_frame>120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Resuscitative Efforts</measure>
    <time_frame>120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Additional Antiarrhythmic Drugs</measure>
    <time_frame>120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Sudden Cardiac Death</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Standard Of Care Drug Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Metoprolol instead Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Epinephrine (1 mg) IV additional doses</description>
    <arm_group_label>Standard Of Care Drug Epinephrine</arm_group_label>
    <other_name>adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses</description>
    <arm_group_label>IV Metoprolol instead Epinephrine</arm_group_label>
    <other_name>lopressor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients age &gt; 18 years of age who develop an in-hospital VF or pVT arrest which&#xD;
             persists after three or more precordial shocks.&#xD;
&#xD;
          -  Patients who develop an in-hospital cardiac arrest due to asystole or PEA which&#xD;
             subsequently converts to VF or pVT will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age &lt; 18 years of age&#xD;
&#xD;
          -  Patients who develop VF or pVT in the emergency room, operating room or surgical&#xD;
             intensive care unit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Haines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>July 18, 2013</results_first_submitted>
  <results_first_submitted_qc>March 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>David Haines, MD</investigator_full_name>
    <investigator_title>Coordinator</investigator_title>
  </responsible_party>
  <keyword>Cardiac arrest</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>Pulseless Ventricular Tachycardia</keyword>
  <keyword>Cardiopulmonary resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients in the ventricular tacchycardia refractory to shock with beta blocker</recruitment_details>
      <pre_assignment_details>After the patient was refractory to treatment of the Epinephrine the patient would receive medication called Metroprolol</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Additional Doses of Epinephrine</title>
          <description>Epinephrine: additional doses Epinephrine (1 mg) IV given as part of standard of care in cardiac arrest</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol Instead of Additional Epinephrine Doses</title>
          <description>Metoprolol: Metoprolol 5 mg IV (up to two times) instead of additional doses of epinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Additional Epinephrine Doses</title>
          <description>Additional Epinephrine (1 mg) IV doses as part of standard of care in cardiac arrest</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol</title>
          <description>Metoprolol 5 mg IV (up to two doses only) instead of additional epinephrine doses in cardiac arrest</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="21.9"/>
                    <measurement group_id="B2" value="60.8" spread="5.49"/>
                    <measurement group_id="B3" value="63" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Return of Spontaneous Circulation</title>
        <description>The patient will be evaluated for sufficiently stable and organized rhythm and blood pressure.</description>
        <time_frame>After electrical defibrillation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Additional Doses of Epinephrine</title>
            <description>Epinephrine: Additional doses of epinephrine (1 mg IV) given as part of standard of care during cardiac arrest</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Instead of Additional Epinephrine Doses</title>
            <description>Metoprolol 5 mg IV (up to 2 times) instead of additional epinephrine doses</description>
          </group>
        </group_list>
        <measure>
          <title>Return of Spontaneous Circulation</title>
          <description>The patient will be evaluated for sufficiently stable and organized rhythm and blood pressure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival to Hospital Discharge</title>
        <description>the number of patients who are alive at hospital discharge</description>
        <time_frame>from time of arrest to discharge or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Additional Epinephrine Doses</title>
            <description>Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest&#xD;
Epinephrine: Epinephrine (1 mg) IV additional doses</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Instead of Additional Epinephrine Doses</title>
            <description>IV metoprolol 5 mg. (up to 2 times only) during cardiac arrest will be given instead of additional Epinephrine doses&#xD;
Metoprolol: Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses</description>
          </group>
        </group_list>
        <measure>
          <title>Survival to Hospital Discharge</title>
          <description>the number of patients who are alive at hospital discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Additional Doses of Epinephrine</title>
            <description>Epinephrine: Additional doses of epinephrine IV (1 mg) given as part of standard of care in cardiac arrest</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Instead of Additional Epinephrine Doses</title>
            <description>Metoprolol: Metoprolol 5mg IV (up to two times only) instead of additional epinephrine doses</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Precordial Shocks Required After the Administration of Metoprolol or Epinephrine</title>
        <time_frame>120 minutes</time_frame>
        <population>Data point not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Epinephrine Doses</title>
            <description>Additional Epinephrine (1 mg) IV doses as part of standard of care in cardiac arrest</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol 5 mg IV (up to two doses only) instead of additional epinephrine doses in cardiac arrest</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Precordial Shocks Required After the Administration of Metoprolol or Epinephrine</title>
          <population>Data point not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Duration of Resuscitative Efforts</title>
        <time_frame>120 minutes</time_frame>
        <population>Data point not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Epinephrine Doses</title>
            <description>Additional Epinephrine (1 mg) IV doses as part of standard of care in cardiac arrest</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol 5 mg IV (up to two doses only) instead of additional epinephrine doses in cardiac arrest</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Resuscitative Efforts</title>
          <population>Data point not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Additional Antiarrhythmic Drugs</title>
        <time_frame>120 minutes</time_frame>
        <population>Data point not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Epinephrine Doses</title>
            <description>Additional Epinephrine (1 mg) IV doses as part of standard of care in cardiac arrest</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol 5 mg IV (up to two doses only) instead of additional epinephrine doses in cardiac arrest</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Additional Antiarrhythmic Drugs</title>
          <population>Data point not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After Electrical Defibrillation, up to 30 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Additional Doses of Epinephrine</title>
          <description>Epinephrine: Additional doses epinephrine (1 mg IV) as part of standard of care during cardiac arrest</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol Instead of Additional Doses of Epinephrine</title>
          <description>Metoprolol: Metoprolol 5 mg IV (up to two times) instead of additional epinephrine doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination secondary to poor enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Haines, MD</name_or_title>
      <organization>Beaumont</organization>
      <phone>248-898-4198</phone>
      <email>david.haines@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

